Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients

Journal of the American Society of Nephrology

Volumn 20, Issue 3, 2009, Pages 639-644

  Savica, Vincenzo ^a,c   Calò, Lorenzo A ^d   Monardo, Paolo ^c   Davis, Paul A ^e   Granata, Antonio ^b   Santoro, Domenico ^a   Savica, Rodolfo ^a   Musolino, Rosa ^a   Comelli, Maria Cristina ^f   Bellinghieri, Guido ^a  

^a Department of Nephrology ^*  (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Ospedale Papardo   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CMandD Pharma Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; CHITOSAN; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHEWING GUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG BINDING; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; IN VITRO STUDY; LOW DRUG DOSE; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SALIVA LEVEL; VISCOSITY;

EID: 62149116515     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008020130     Document Type: Article

References (23)

1. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131-2138, 2001
2. Emmett M: A comparison of clinically useful phosphorus binders for patients with chronic renal failure. Kidney Int Suppl S25-S32, 2004
3. Li XL, Yang HY, Giachelli CM: Role of sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98: 905-912, 2006
4. Finn WF: Phosphorus management in end-stage renal disease. Semin Dial 18: 8-12, 2005
5. Kuhlmann MK: Practical approaches to management of hyperphosphatemia: Can we improve the current situation? Blood Purif 25: 120-124, 2007
6. Savica V, Calò LA, Monardo P, Santoro D, Bellinghieri G: Phosphate binders and management of hyperphosphatemia in end-stage renal disease. Nephrol Dial Transplant 21: 2065-2068, 2006
7. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcome and practice patterns study (DOPPS). Am J Kidney Dis 44: 34-38, 2004
8. Savica V, Calò LA, Santoro D, Monardo P, Granata A, Bellinghieri G: Salivary phosphate secretion in chronic kidney disease. J Renal Nutr 18: 87-90, 2008
9. Savica V, Calò LA, Caldarera R, Cavaleri A, Granata A, Santoro D, Savica R, Muraca U, Mallamace A, Bellingheri G: Phosphate salivary secretion in hemodialysis patients: Implications for the treatment of hyperphosphatemia. Nephron Physiol 105: 52-55, 2007
10. Uribarri J: Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Semin Dial 20: 295-301, 2007
11. Tharanathan RN, Kittur FS: Chitin: The undisputed biomolecule of great interest. Crit Rev Food Sci Nutr 43: 61-87, 2003
12. Zhang Y, Zhang M: Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J Biomed Mater Res 62: 378-386, 2002
13. Grabovac V, Guggi D, Bernkop-Schnürch A: Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 57: 1713-1723, 2005
14. Shields KM, Smock N, McQueen CE, Bryant PJ: Chitosan for weight loss and cholesterol management. Am J Health Syst Pharm 60: 1310-1312, 1315-1316, 2003
15. Liao FH, Shieh MJ, Chang NC, Chien YW: Chitosan supplementation lowers serum lipids and maintains normal calcium, magnesium and iron status in hyperlipidemic patients. Nutr Res 27: 146-151, 2007
16. Puy CL: The role of saliva in maintaining oral health and as an aid to diagnosis. Med Oral Patol Oral Cir Bucal 11: E449-E455, 2006
17. Lac G: Saliva assays in clinical and research biology. Pathol Biol 49: 660-667, 2001
18. Kho HS, Lee SW, Chung SC, Kim YK: Oral manifestations and salivary flow rate and buffer capacity in patients with end-stage renal disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88: 316-319, 1999
19. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev (2): CD000011, 2008
20. Slatopolsky E, Brown A, Dusso A: Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 37[Suppl 2]: S54-S57, 2001
21. Moallem E, Kilav R, Silver J, Naveh-Many T: RNA protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273: 5253-5259, 1998
22. Jayakumar R, New N, Tokura S, Tamura H: Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 40: 175-181, 2007
23. Maggi L, Segale L, Conti S, Ochoa Machiste E, Salini A, Conte U: Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device. Eur J Pharm Sci 24: 487-493, 2005